Abstract
BACKGROUND
Mycoplasma pneumoniae-induced rash and mucositis (MIRM) is a relatively newly recognized clinical entity that typically presents with predominant mucositis accompanied by variable cutaneous involvement 7-9 days after the onset of prodromal symptoms. There are no evidence-based guidelines for treatment, and current standards of care may include supportive therapy, antibiotics, corticosteroids, and intravenous immunoglobulin .
OBJECTIVE
This case series aims to describe the potential efficacy of cyclosporine A (CsA) in the treatment of MIRM.
METHODS
The present case series details our use of CsA early in the course of MIRM in 3 pediatric patients.
RESULTS
Rapid clinical resolution was observed following CsA therapy.
CONCLUSIONS
We suggest that early initiation of CsA may be an effective therapeutic option for MIRM.
TY - JOUR
T1 - Treatment of Mycoplasma pneumoniae-Induced Rash and Mucositis With Cyclosporine [Formula: see text].
AU - Li,Heidi Oi-Yee,
AU - Colantonio,Sophia,
AU - Ramien,Michele L,
Y1 - 2019/09/10/
PY - 2019/9/11/pubmed
PY - 2020/8/25/medline
PY - 2019/9/11/entrez
KW - Fuchs syndrome
KW - MIRM
KW - MPAM
KW - Mycoplasma pneumoniae-associated mucositis
KW - Mycoplasma pneumoniae-induced rash and mucositis
KW - SJS
KW - Stevens-Johnson syndrome
KW - case series
KW - cyclosporine
KW - cyclosporine A
KW - mucositis
KW - mycoplasma
KW - pediatric
KW - therapeutics
SP - 608
EP - 612
JF - Journal of cutaneous medicine and surgery
JO - J Cutan Med Surg
VL - 23
IS - 6
N2 - BACKGROUND: Mycoplasma pneumoniae-induced rash and mucositis (MIRM) is a relatively newly recognized clinical entity that typically presents with predominant mucositis accompanied by variable cutaneous involvement 7-9 days after the onset of prodromal symptoms. There are no evidence-based guidelines for treatment, and current standards of care may include supportive therapy, antibiotics, corticosteroids, and intravenous immunoglobulin . OBJECTIVE: This case series aims to describe the potential efficacy of cyclosporine A (CsA) in the treatment of MIRM. METHODS: The present case series details our use of CsA early in the course of MIRM in 3 pediatric patients. RESULTS: Rapid clinical resolution was observed following CsA therapy. CONCLUSIONS: We suggest that early initiation of CsA may be an effective therapeutic option for MIRM.
SN - 1615-7109
UR - https://www.unboundmedicine.com/medline/citation/31502864/Treatment_of_Mycoplasma_pneumoniae_Induced_Rash_and_Mucositis_With_Cyclosporine_[Formula:_see_text]_
L2 - https://journals.sagepub.com/doi/10.1177/1203475419874444?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed
DB - PRIME
DP - Unbound Medicine
ER -